CA1102345A - Traduction non-disponible - Google Patents

Traduction non-disponible

Info

Publication number: CA1102345A
Authority: CA; Canada
Prior art keywords: process according; group; phenyl; formula; compound
Prior art date: 1977-12-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA318,112A

Other languages

English (en)

Inventor

Nicholas S. Bodor

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Interx Research Corp

Original Assignee

Interx Research Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-12-16

Filing date

1978-12-18

Publication date

1981-06-02

1978-12-18 Application filed by Interx Research Corp filed Critical Interx Research Corp

1981-06-02 Application granted granted Critical

1981-06-02 Publication of CA1102345A publication Critical patent/CA1102345A/fr

Status Expired legal-status Critical Current

Links

230000001262 anti-secretory effect Effects 0.000 title abstract description 8
230000001747 exhibiting effect Effects 0.000 title abstract description 4
229940121948 Muscarinic receptor antagonist Drugs 0.000 title description 3
239000000812 cholinergic antagonist Substances 0.000 title description 3
150000001875 compounds Chemical class 0.000 claims abstract description 69
150000001412 amines Chemical class 0.000 claims abstract description 28
125000001424 substituent group Chemical group 0.000 claims abstract description 20
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 18
229910052736 halogen Inorganic materials 0.000 claims abstract description 17
125000000217 alkyl group Chemical group 0.000 claims abstract description 15
125000005843 halogen group Chemical group 0.000 claims abstract description 15
150000002367 halogens Chemical class 0.000 claims abstract description 15
229910052799 carbon Inorganic materials 0.000 claims abstract description 13
125000005041 acyloxyalkyl group Chemical group 0.000 claims abstract description 11
125000004183 alkoxy alkyl group Chemical group 0.000 claims abstract description 10
125000004181 carboxyalkyl group Chemical group 0.000 claims abstract description 10
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 10
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 10
125000003118 aryl group Chemical group 0.000 claims abstract description 9
239000001257 hydrogen Substances 0.000 claims abstract description 9
125000001188 haloalkyl group Chemical group 0.000 claims abstract description 8
125000000392 cycloalkenyl group Chemical group 0.000 claims abstract description 6
125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 5
229910004679 ONO2 Inorganic materials 0.000 claims abstract description 4
125000003342 alkenyl group Chemical group 0.000 claims abstract description 4
150000001450 anions Chemical class 0.000 claims abstract description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 4
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 4
125000003107 substituted aryl group Chemical group 0.000 claims abstract description 4
238000000034 method Methods 0.000 claims description 85
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 35
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 23
125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims description 23
229910052757 nitrogen Inorganic materials 0.000 claims description 23
238000002360 preparation method Methods 0.000 claims description 22
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 13
235000019270 ammonium chloride Nutrition 0.000 claims description 11
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 10
-1 tri-propoxyethylamine Chemical compound 0.000 claims description 10
150000003512 tertiary amines Chemical class 0.000 claims description 9
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 8
125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 8
238000005342 ion exchange Methods 0.000 claims description 7
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
150000003335 secondary amines Chemical class 0.000 claims description 6
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
229910052760 oxygen Inorganic materials 0.000 claims description 5
239000001301 oxygen Substances 0.000 claims description 5
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 4
125000006225 propoxyethyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 4
239000011541 reaction mixture Substances 0.000 claims description 4
150000001350 alkyl halides Chemical class 0.000 claims description 3
JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 claims description 3
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 3
VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 claims description 2
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 2
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 2
CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 2
PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 2
SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 claims description 2
235000013350 formula milk Nutrition 0.000 claims 41
239000000126 substance Substances 0.000 claims 31
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 6
AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 claims 4
AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 claims 4
229950000688 phenothiazine Drugs 0.000 claims 4
PXHHIBMOFPCBJQ-UHFFFAOYSA-N 1,2-dimethylpyrrolidine Chemical compound CC1CCCN1C PXHHIBMOFPCBJQ-UHFFFAOYSA-N 0.000 claims 3
WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 claims 3
ZHKJHQBOAJQXQR-UHFFFAOYSA-N 1H-azirine Chemical compound N1C=C1 ZHKJHQBOAJQXQR-UHFFFAOYSA-N 0.000 claims 3
VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 claims 3
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
150000002431 hydrogen Chemical class 0.000 claims 3
229940113083 morpholine Drugs 0.000 claims 3
XBLVHTDFJBKJLG-UHFFFAOYSA-N Ethyl nicotinate Chemical compound CCOC(=O)C1=CC=CN=C1 XBLVHTDFJBKJLG-UHFFFAOYSA-N 0.000 claims 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
150000001542 azirines Chemical class 0.000 claims 2
150000002460 imidazoles Chemical class 0.000 claims 2
150000002518 isoindoles Chemical class 0.000 claims 2
150000002780 morpholines Chemical class 0.000 claims 2
150000002990 phenothiazines Chemical class 0.000 claims 2
150000003020 phtalazines Chemical class 0.000 claims 2
150000003217 pyrazoles Chemical class 0.000 claims 2
150000003233 pyrroles Chemical class 0.000 claims 2
150000003510 tertiary aliphatic amines Chemical class 0.000 claims 2
125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 claims 1
FNEVYPWFIHXGCD-UHFFFAOYSA-N 2-propoxy-n,n-bis(2-propoxyethyl)ethanamine Chemical compound CCCOCCN(CCOCCC)CCOCCC FNEVYPWFIHXGCD-UHFFFAOYSA-N 0.000 claims 1
WRJPSSPFHGNBMG-UHFFFAOYSA-N acetic acid 1-azabicyclo[2.2.2]octan-3-yl ester Chemical compound C1CC2C(OC(=O)C)CN1CC2 WRJPSSPFHGNBMG-UHFFFAOYSA-N 0.000 claims 1
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
150000002475 indoles Chemical class 0.000 claims 1
150000002537 isoquinolines Chemical class 0.000 claims 1
150000003854 isothiazoles Chemical class 0.000 claims 1
150000002545 isoxazoles Chemical class 0.000 claims 1
150000002988 phenazines Chemical class 0.000 claims 1
150000003216 pyrazines Chemical class 0.000 claims 1
150000004892 pyridazines Chemical class 0.000 claims 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
150000003222 pyridines Chemical class 0.000 claims 1
150000003230 pyrimidines Chemical class 0.000 claims 1
150000003235 pyrrolidines Chemical class 0.000 claims 1
150000003248 quinolines Chemical class 0.000 claims 1
150000008584 quinuclidines Chemical class 0.000 claims 1
150000005619 secondary aliphatic amines Chemical class 0.000 claims 1
230000001078 anti-cholinergic effect Effects 0.000 abstract description 10
230000001225 therapeutic effect Effects 0.000 abstract description 3
231100000053 low toxicity Toxicity 0.000 abstract description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 16
230000004044 response Effects 0.000 description 16
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 15
101150041968 CDC13 gene Proteins 0.000 description 14
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
229960004373 acetylcholine Drugs 0.000 description 14
239000000460 chlorine Substances 0.000 description 13
230000000694 effects Effects 0.000 description 13
239000000203 mixture Substances 0.000 description 12
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 11
239000007787 solid Substances 0.000 description 10
239000005557 antagonist Substances 0.000 description 9
235000002639 sodium chloride Nutrition 0.000 description 9
239000012043 crude product Substances 0.000 description 8
150000003839 salts Chemical class 0.000 description 8
239000000047 product Substances 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
239000007788 liquid Substances 0.000 description 6
239000000243 solution Substances 0.000 description 6
FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 6
241000282326 Felis catus Species 0.000 description 5
239000002253 acid Substances 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000003814 drug Substances 0.000 description 5
239000007858 starting material Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
230000036772 blood pressure Effects 0.000 description 4
229910052801 chlorine Inorganic materials 0.000 description 4
238000001816 cooling Methods 0.000 description 4
238000012360 testing method Methods 0.000 description 4
BZLBBZLOMXKMTA-UHFFFAOYSA-N 1-azoniabicyclo[2.2.2]octane;chloride Chemical compound Cl.C1CC2CCN1CC2 BZLBBZLOMXKMTA-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
241000700199 Cavia porcellus Species 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
229930040373 Paraformaldehyde Natural products 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
150000001266 acyl halides Chemical class 0.000 description 3
229910052794 bromium Inorganic materials 0.000 description 3
KFYXXCWHKINEIC-UHFFFAOYSA-N chloromethyl 2-phenylacetate Chemical compound ClCOC(=O)CC1=CC=CC=C1 KFYXXCWHKINEIC-UHFFFAOYSA-N 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
210000003405 ileum Anatomy 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
125000004433 nitrogen atom Chemical group N* 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
229920002866 paraformaldehyde Polymers 0.000 description 3
239000000376 reactant Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
229930003347 Atropine Natural products 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
244000025254 Cannabis sativa Species 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
241001295925 Gegenes Species 0.000 description 2
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229940022663 acetate Drugs 0.000 description 2
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
229960000396 atropine Drugs 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000000975 dye Substances 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
239000008101 lactose Substances 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
229960002900 methylcellulose Drugs 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
238000012552 review Methods 0.000 description 2
230000007017 scission Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
239000002731 stomach secretion inhibitor Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
WLAMNBDJUVNPJU-UHFFFAOYSA-M 2-methylbutyrate Chemical compound CCC(C)C([O-])=O WLAMNBDJUVNPJU-UHFFFAOYSA-M 0.000 description 1
ZLWIMPFRPFWOGK-UHFFFAOYSA-N 2-methylisoindole Chemical compound C1=CC=CC2=CN(C)C=C21 ZLWIMPFRPFWOGK-UHFFFAOYSA-N 0.000 description 1
UBLAMKHIFZBBSS-UHFFFAOYSA-N 3-Methylbutyl pentanoate Chemical compound CCCCC(=O)OCCC(C)C UBLAMKHIFZBBSS-UHFFFAOYSA-N 0.000 description 1
CLMSHAWYULIVFQ-UHFFFAOYSA-N 3-bromo-3h-2-benzofuran-1-one Chemical compound C1=CC=C2C(Br)OC(=O)C2=C1 CLMSHAWYULIVFQ-UHFFFAOYSA-N 0.000 description 1
SJRJJKPEHAURKC-UHFFFAOYSA-O 4-methylmorpholin-4-ium Chemical compound C[NH+]1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-O 0.000 description 1
YCPXWRQRBFJBPZ-UHFFFAOYSA-N 5-sulfosalicylic acid Chemical class OC(=O)C1=CC(S(O)(=O)=O)=CC=C1O YCPXWRQRBFJBPZ-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
102100038916 Caspase-5 Human genes 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
241000861718 Chloris <Aves> Species 0.000 description 1
241000206575 Chondrus crispus Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
101100112336 Homo sapiens CASP5 gene Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 description 1
101100273286 Mus musculus Casp4 gene Proteins 0.000 description 1
QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
XLBIBBZXLMYSFF-UHFFFAOYSA-M Propantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 XLBIBBZXLMYSFF-UHFFFAOYSA-M 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
206010047513 Vision blurred Diseases 0.000 description 1
DVIVREXZQRJKIT-UHFFFAOYSA-I [Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]S([O-])(=O)=O Chemical compound [Ca++].[Ca++].[Ca++].[O-]P([O-])([O-])=O.[O-]S([O-])(=O)=O DVIVREXZQRJKIT-UHFFFAOYSA-I 0.000 description 1
GXCKQVNPVQWIHP-UHFFFAOYSA-N [Cl-].C[NH+]1C2=CC=CC=C2SC=2C=CC=CC1=2 Chemical compound [Cl-].C[NH+]1C2=CC=CC=C2SC=2C=CC=CC1=2 GXCKQVNPVQWIHP-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
239000003513 alkali Substances 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
230000002152 alkylating effect Effects 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
239000003957 anion exchange resin Substances 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
239000002585 base Substances 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
235000012216 bentonite Nutrition 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
235000010338 boric acid Nutrition 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
239000001175 calcium sulphate Substances 0.000 description 1
235000011132 calcium sulphate Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229950009941 chloralose Drugs 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
230000006378 damage Effects 0.000 description 1
125000005265 dialkylamine group Chemical group 0.000 description 1
238000004821 distillation Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
206010013781 dry mouth Diseases 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
238000001914 filtration Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
229960002154 guar gum Drugs 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
ATADHKWKHYVBTJ-UHFFFAOYSA-N hydron;4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol;chloride Chemical compound Cl.CNCC(O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-UHFFFAOYSA-N 0.000 description 1
BTJRKNUKPQBLAL-UHFFFAOYSA-N hydron;4-methylmorpholine;chloride Chemical compound Cl.CN1CCOCC1 BTJRKNUKPQBLAL-UHFFFAOYSA-N 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
239000011630 iodine Substances 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
235000005772 leucine Nutrition 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
238000002156 mixing Methods 0.000 description 1
235000013379 molasses Nutrition 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
GDZXBRCDCJUSRH-UHFFFAOYSA-N o-(chloromethyl) ethanethioate Chemical compound CC(=S)OCCl GDZXBRCDCJUSRH-UHFFFAOYSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
229940099209 probanthine Drugs 0.000 description 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 1
UCBCBMOOIZMOTR-UHFFFAOYSA-N pyrazine;pyridine Chemical compound C1=CC=NC=C1.C1=CN=CC=N1 UCBCBMOOIZMOTR-UHFFFAOYSA-N 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229960005349 sulfur Drugs 0.000 description 1
235000001508 sulfur Nutrition 0.000 description 1
210000004243 sweat Anatomy 0.000 description 1
DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
229910052716 thallium Inorganic materials 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
125000005490 tosylate group Chemical group 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000005292 vacuum distillation Methods 0.000 description 1
230000002541 vasodepressive effect Effects 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/90—Benzo [c] furans; Hydrogenated benzo [c] furans with an oxygen atom in position 1 and a nitrogen atom in position 3, or vice versa
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Neurology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pyrrole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Hydrogenated Pyridines (AREA)

CA318,112A 1977-12-16 1978-12-18 Traduction non-disponible Expired CA1102345A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US86121077A	1977-12-16	1977-12-16
US861,210		1977-12-16

Publications (1)

Publication Number	Publication Date
CA1102345A true CA1102345A (fr)	1981-06-02

Family

ID=25335183

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA318,112A Expired CA1102345A (fr)	1977-12-16	1978-12-18	Traduction non-disponible

Country Status (15)

Country	Link
JP (1)	JPS5498711A (fr)
AR (1)	AR222478A1 (fr)
AT (1)	AT366380B (fr)
AU (1)	AU531835B2 (fr)
CA (1)	CA1102345A (fr)
DE (1)	DE2854308A1 (fr)
DK (1)	DK534178A (fr)
ES (1)	ES476048A1 (fr)
FR (1)	FR2422624A1 (fr)
GB (1)	GB2010270B (fr)
IE (1)	IE48012B1 (fr)
IT (1)	IT1101735B (fr)
NL (1)	NL7812257A (fr)
NO (1)	NO148776C (fr)
SE (1)	SE436027B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5962505A (en) *	1998-08-31	1999-10-05	Bobrove; Arthur M.	Method for treating hot flashes in humans
US6433003B1 (en)	1999-04-23	2002-08-13	Arthur M. Bobrove	Method for treating hyperhidrosis in mammals

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3045055A1 (de) *	1980-11-29	1982-07-01	Celamerck Gmbh & Co Kg, 6507 Ingelheim	Heterocyclische verbindungen
JPS5993075A (ja) *	1982-11-18	1984-05-29	Shionogi & Co Ltd	１−フタリジル−５−フルオロウラシル誘導体の製造法
US4824676A (en) *	1984-10-11	1989-04-25	Schering Corporation	Physiological means of enhancing transdermal delivery of drugs
US5008111A (en) *	1984-10-11	1991-04-16	Schering Corporation	Physiological means of enhancing transdermal delivery of drugs
FR2703046B1 (fr) *	1993-03-26	1995-05-05	Poudres & Explosifs Ste Nale	Procédé de préparation d'oxalates et d'halogénoglyoxalates alpha- monohalogénés et nouveaux oxalates et halogénoglyoxalates alpha-monohalogénés .
AUPN814496A0 (en)	1996-02-19	1996-03-14	Monash University	Dermal penetration enhancer
AR044134A1 (es) *	2003-05-02	2005-08-24	Novartis Ag	Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
MX2007015255A (es)	2005-06-03	2008-02-22	Acrux Dds Pty Ltd	Metodo y composicion para administracion transdermica de un farmaco.
BRPI0620844A2 (pt) *	2005-12-30	2011-11-29	Ranbaxy Lab Ltd	compostos antagonistas dos receptores muscarìnicos, seus métodos de preparação, composições farmacêuticas compreendendo os mesmos, usos dos referidos compostos na preparação de medicamentos
PT2219603E (pt)	2007-11-02	2014-09-02	Acrux Dds Pty Ltd	Piperazinas como agentes antimalariais
WO2014054058A2 (fr) *	2012-10-05	2014-04-10	Sphaera Pharma Pvt. Ltd.	Nouveaux composés, leur synthèse et leurs utilisations
DE102013013397A1 (de)	2013-08-13	2015-03-12	Epinamics Gmbh	Aerosolspender für transdermal wirkende pharmazeutische Zusammensetzungen
CN110041264A (zh) *	2019-04-11	2019-07-23	贺州学院	一种金刚烷基咪唑类离子液体及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL101555C (fr) *	1955-03-19
BE798253A (nl) *	1973-04-16	1973-10-16	Bekaert Sa Nv	Zitmeubel
US3998815A (en) *	1974-06-24	1976-12-21	Interx Research Corporation	1-hydrocarbonoyloxymethyl-3-carbamoyl or 3-carboethoxy-pyridinium salts

1978
- 1978-11-29 DK DK534178A patent/DK534178A/da not_active Application Discontinuation
- 1978-12-12 IT IT30735/78A patent/IT1101735B/it active
- 1978-12-15 ES ES476048A patent/ES476048A1/es not_active Expired
- 1978-12-15 AR AR274836A patent/AR222478A1/es active
- 1978-12-15 NO NO784229A patent/NO148776C/no unknown
- 1978-12-15 JP JP15601378A patent/JPS5498711A/ja active Pending
- 1978-12-15 DE DE19782854308 patent/DE2854308A1/de not_active Withdrawn
- 1978-12-15 SE SE7812911A patent/SE436027B/sv unknown
- 1978-12-18 AU AU42646/78A patent/AU531835B2/en not_active Expired
- 1978-12-18 GB GB7848850A patent/GB2010270B/en not_active Expired
- 1978-12-18 FR FR7835596A patent/FR2422624A1/fr active Granted
- 1978-12-18 AT AT0901478A patent/AT366380B/de active
- 1978-12-18 IE IE2499/78A patent/IE48012B1/en unknown
- 1978-12-18 CA CA318,112A patent/CA1102345A/fr not_active Expired
- 1978-12-18 NL NL7812257A patent/NL7812257A/xx not_active Application Discontinuation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5962505A (en) *	1998-08-31	1999-10-05	Bobrove; Arthur M.	Method for treating hot flashes in humans
US6433003B1 (en)	1999-04-23	2002-08-13	Arthur M. Bobrove	Method for treating hyperhidrosis in mammals

Also Published As

Publication number	Publication date
DE2854308A1 (de)	1979-06-21
ES476048A1 (es)	1979-11-01
IT7830735A0 (it)	1978-12-12
AT366380B (de)	1982-04-13
AU531835B2 (en)	1983-09-08
AU4264678A (en)	1979-06-21
NL7812257A (nl)	1979-06-19
AR222478A1 (es)	1981-05-29
NO148776B (no)	1983-09-05
JPS5498711A (en)	1979-08-03
ATA901478A (de)	1981-08-15
NO148776C (no)	1983-12-14
IT1101735B (it)	1985-10-07
IE782499L (en)	1979-06-16
GB2010270B (en)	1982-10-20
IE48012B1 (en)	1984-09-05
FR2422624B1 (fr)	1983-10-14
NO784229L (no)	1979-06-19
SE7812911L (sv)	1979-06-17
FR2422624A1 (fr)	1979-11-09
GB2010270A (en)	1979-06-27
DK534178A (da)	1979-06-17
SE436027B (sv)	1984-11-05

Legal Events

Date	Code	Title	Description
1998-06-02	MKEX	Expiry

Publication	Publication Date	Title
CA1102345A (fr)	1981-06-02	Traduction non-disponible
US4225591A (en)	1980-09-30	2,6-Diaminonebularines
CA2078264A1 (fr)	1993-03-17	Derives a substitution d'antagonistes de piperazinylcamphresulfonyloxytocine
DE3236065A1 (de)	1983-04-14	Dioximinocephalosporine
US6307053B1 (en)	2001-10-23	Process for preparing imidacloprid
DE2736471A1 (de)	1978-08-17	Ungesaettigte 7-acylamido-3-cephem- 4-carbonsaeure-derivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel und veterinaermittel
DE2916140A1 (de)	1979-10-31	1,3-diphenyl-2-iminoimidazolidine und 1,3-diphenyl-2-iminohexahydropyrimidine, verfahren zu ihrer herstellung und solche enthaltende arzneimittel
US3349082A (en)	1967-10-24	Mannich bases of rifamycin sv
DE3005888A1 (de)	1980-08-28	3-phosphonocephalosporansaeure- derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische mittel
JPS6372687A (ja)	1988-04-02	（ベンゾフラン−２−イル）イミダゾ−ル化合物、その製造法及びそれを含有する医薬組成物
CS246074B2 (en)	1986-10-16	Method of n-iminopyridinium's betaines preparation
KR0178957B1 (ko)	1999-03-20	페넴 화합물
DE2857816C2 (de)	1985-05-09	7ß-(substituierte-Isothiazol)thioacetamido-7-methoxy(alkylsubstituierte-tetraz olyl)thiomethyl-&Delta;&uarr;3&uarr;-cephem-4-carbonsäuren, Verfahren zu ihrer Herstellung und deren Verwendung
US2759943A (en)	1956-08-21	Derivatives of 2-n-methyl-1, 2, 3, 4-tetrahydro-gamma-carbolines
US3725419A (en)	1973-04-03	Quinuclidylalkyl esters
AU636034B2 (en)	1993-04-08	6-subsituted purinyl piperazine derivatives
DD210054A5 (de)	1984-05-30	Verfahren zur herstellung neuer derivate des cephalosporin
HU197843B (en)	1989-06-28	Process for producing pharmaceutical compositions comprising 2-alkoxy-n-(1-azabicyclo/2.2.2/oct-3-yl)-benzamide-n-oxide derivatives
CN116217553B (zh)	2025-03-28	一种三嗪酮类化合物及其制备方法和应用
KR0177844B1 (ko)	1999-03-20	항균성 페넴화합물
US3133067A (en)	1964-05-12	1-monocarbocyclic aryl-4-thiocarbam-ylpiperazines and intermediates and processes therefor
US3322768A (en)	1967-05-30	Aralkyl piperazines and salts thereof
US4477449A (en)	1984-10-16	Certain 1,8-naphthyridine compounds useful as antibacterial agents
KR880001105B1 (ko)	1988-06-29	1-벤질-4-[4-(2-피리미디닐아미노)벤질]-2,3-디옥소피페라진 유도체의 제조방법
AT391695B (de)	1990-11-12	Neue verbindungen, ihre herstellung und diese enthaltende pharmazeutische zubereitungen

CA1102345A - Traduction non-disponible - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=25335183

Family Applications (1)

Country Status (15)

Cited By (2)

Families Citing this family (13)

Family Cites Families (3)

Cited By (2)

Also Published As

Similar Documents

Legal Events